Phase 2/3Completed
A Study of MG1111 in Healthy Children
A Phase II/III, Single-blind(Stage 1), Double-blinded(Stage 2), Randomized, Active-controlled, Dose-escalation(Stage 1), Non-inferiority(Stage 2) Study to Evaluate Immunogenicity and Safety of MG1111 in Healthy Children
- Sponsor
- Green Cross Corporation (Industry)
- Enrollment
- 814 enrolled
- Conditions
- Healthy Children
- Interventions
- Varicella Vaccine
- Ages
- children
- Registry
- NCT03375502
Full record on ClinicalTrials.gov
From the registry
To assess the safety of MG1111 and to evaluate immunological non-inferiority of MG1111 versus comparator
Primary outcomes
- Proportion of subjects who achieved seroconversion
History
Last registry update
Study completion
Primary completion
Registered
Started